KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Equity Ratio (2016 - 2026)

Biocryst Pharmaceuticals filings provide 16 years of Equity Ratio readings, the most recent being 0.23 for Q4 2025.

  • On a quarterly basis, Equity Ratio rose 76.12% to 0.23 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.23, a 76.12% increase, with the full-year FY2025 number at 0.23, up 76.12% from a year prior.
  • Equity Ratio hit 0.23 in Q4 2025 for Biocryst Pharmaceuticals, up from 0.87 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.18 in Q4 2021 to a low of 1.02 in Q1 2024.
  • Median Equity Ratio over the past 5 years was 0.69 (2023), compared with a mean of 0.65.
  • Biggest five-year swings in Equity Ratio: plummeted 1087.13% in 2021 and later surged 76.12% in 2025.
  • Biocryst Pharmaceuticals' Equity Ratio stood at 0.18 in 2021, then crashed by 194.46% to 0.54 in 2022, then tumbled by 64.51% to 0.88 in 2023, then fell by 10.13% to 0.97 in 2024, then surged by 76.12% to 0.23 in 2025.
  • The last three reported values for Equity Ratio were 0.23 (Q4 2025), 0.87 (Q3 2025), and 0.92 (Q2 2025) per Business Quant data.